Related Experiment Videos
Response to treatment of congenital adrenal hyperplasia in infancy
1Department of Child Health, University of Wales College of Medicine, Heath Park, Cardiff.
Insights
Starting congenital adrenal hyperplasia treatment with replacement hydrocortisone doses in infants avoids overtreatment and growth suppression. This approach maintains biochemical control and satisfactory growth, even as dosage is reduced over time.
Area of Science:
- Pediatrics
- Endocrinology
- Genetics
Background:
- Congenital adrenal hyperplasia (CAH) is a group of genetic disorders affecting the adrenal glands.
- Standard treatment for CAH involves glucocorticoid replacement therapy, typically hydrocortisone.
- Concerns exist regarding potential overtreatment and growth suppression in infants receiving high initial doses.
Purpose of the Study:
- To evaluate the efficacy and safety of initiating hydrocortisone replacement therapy at standard doses in infants with CAH.
- To determine if this approach avoids overtreatment and growth suppression.
- To assess long-term biochemical control and growth outcomes.
Main Methods:
- Nine infants diagnosed with CAH were enrolled.
- Hydrocortisone was administered at replacement doses (20.6-32.6 mg/m2/day) from the start, without an initial high-dose period.
- Plasma adrenal steroid concentrations, hydrocortisone dosage, and growth parameters were monitored over time.
Main Results:
- Plasma adrenal steroid concentrations normalized within 3 months of initiating treatment.
- Adequate biochemical control was achieved and maintained.
- Satisfactory growth was observed, with the mean hydrocortisone dose decreasing to 15 mg/m2/day by age 3 years.
Conclusions:
- Initiating hydrocortisone replacement therapy at standard doses in infants with CAH is effective in achieving biochemical control.
- This dosing strategy appears to prevent overtreatment and growth suppression.
- Allowing hydrocortisone dosage to decrease relative to body surface area is a viable approach for managing CAH in infants.
Abstract:
Nine infants with congenital adrenal hyperplasia were started on replacement doses of hydrocortisone (20.6-32.6 mg/m2/day) without receiving a high dose for an initial period first. Plasma adrenal steroid concentrations fell to acceptable levels by 3 months of age. Adequate biochemical control was maintained and satisfactory growth achieved even though the mean dose of hydrocortisone had been reduced to 15 mg/m2/day by the age of 3 years. Inadvertent overtreatment and growth suppression in infants with congenital adrenal hyperplasia may be avoided by using replacement doses from the start, and by permitting the relative dose of hydrocortisone to fall as the body surface area increases during the first year of life.